Literature DB >> 25941574

B cells for cancer immunotherapy.

Jiusheng Deng1, Jacques Galipeau2.   

Abstract

We have engineered a novel fusion cytokine named GIFT4 derived from GM-CSF and IL-4, and displaying robust gain-of-function immunostimulatory effects on B cells. GIFT4-programmed B cells have a unique identity and potent capacity to elicit a tumoricidal - cell response, thus comprising a novel B cell-based cancer immunotherapeutic approach.

Entities:  

Keywords:  B cells; GIFT4; cancer immunotherapy; fusion cytokine

Year:  2014        PMID： 25941574      PMCID： PMC4292730          DOI： 10.4161/21624011.2014.955702

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF-β receptor II induce potent antitumor immunity.

Authors:  Claudia Penafuerte; Spencer Ng; Norma Bautista-Lopez; Elena Birman; Kathy Forner; Jacques Galipeau
Journal:  Cancer Res       Date:  2012-01-12       Impact factor: 12.701

2.  Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction.

Authors:  Kei Tomihara; Takako Shin; Vincent J Hurez; Hideo Yagita; Drew M Pardoll; Bin Zhang; Tyler J Curiel; Tahiro Shin
Journal:  Aging Cell       Date:  2011-11-28       Impact factor: 9.304

3.  A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties.

Authors:  Moutih Rafei; Jeremy Hsieh; Simone Zehntner; Mengyang Li; Kathy Forner; Elena Birman; Marie-Noëlle Boivin; Yoon Kow Young; Claude Perreault; Jacques Galipeau
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

4.  Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.

Authors:  Claire Germain; Sacha Gnjatic; Fella Tamzalit; Samantha Knockaert; Romain Remark; Jérémy Goc; Alice Lepelley; Etienne Becht; Sandrine Katsahian; Geoffray Bizouard; Pierre Validire; Diane Damotte; Marco Alifano; Pierre Magdeleinat; Isabelle Cremer; Jean-Luc Teillaud; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

5.  B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.

Authors:  David J DiLillo; Koichi Yanaba; Thomas F Tedder
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

Review 6.  CAR T cells: driving the road from the laboratory to the clinic.

Authors:  Eleanor J Cheadle; Hannah Gornall; Vania Baldan; Vivien Hanson; Robert E Hawkins; David E Gilham
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.

Authors:  Jiusheng Deng; Shala Yuan; Andrea Pennati; Jordan Murphy; Jian Hui Wu; David Lawson; Jacques Galipeau
Journal:  Cancer Res       Date:  2014-06-17       Impact factor: 12.701

Review 8.  B cell regulation of anti-tumor immune response.

Authors:  Yu Zhang; Richard Morgan; Eckhard R Podack; Joseph Rosenblatt
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

9.  Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.

Authors:  Monica Bodogai; Catalina Lee Chang; Katarzyna Wejksza; Jinping Lai; Maria Merino; Robert P Wersto; Ronald E Gress; Andrew C Chan; Charles Hesdorffer; Arya Biragyn
Journal:  Cancer Res       Date:  2013-01-30       Impact factor: 12.701

10.  Advances in human B cell phenotypic profiling.

Authors:  Denise A Kaminski; Chungwen Wei; Yu Qian; Alexander F Rosenberg; Ignacio Sanz
Journal:  Front Immunol       Date:  2012-10-10       Impact factor: 7.561
  10 in total
  2 in total

1.  The significance of cytokine-producing B cells in breast tumor-draining lymph nodes.

Authors:  Fereshteh Mehdipour; Mahboobeh Razmkhah; Zahra Faghih; Mandana Bagheri; Abdol-Rasoul Talei; Abbas Ghaderi
Journal:  Cell Oncol (Dordr)       Date:  2019-03-08       Impact factor: 6.730

Review 2.  Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.

Authors:  Liang Guo; Chuanlei Wang; Xiang Qiu; Xiaoyu Pu; Pengyu Chang
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.